Esketamine for depression: should the horizon be expanded to posttraumatic stress disorder?
Saved in:
| Title: | Esketamine for depression: should the horizon be expanded to posttraumatic stress disorder? |
|---|---|
| Authors: | Rothärmel, Maud (AUTHOR), Berkovitch, Lucie (AUTHOR), El-Hage, Wissam (AUTHOR), Bui, Eric (AUTHOR) |
| Source: | International Journal of Mental Health. 2026, Vol. 55 Issue 1, p1-4. 4p. |
| Subjects: | Prevention of mental depression, Post-traumatic stress disorder, Ketamine, Intranasal administration, Suicidal ideation, Patient safety, Neuroplasticity, Intravenous therapy, Experimental design, Learning strategies, Pathological psychology, Comorbidity |
| Abstract: | This article focuses on the clinical use of ketamine and its enantiomer esketamine in treating treatment-resistant depression (TRD) and explores their potential application in posttraumatic stress disorder (PTSD). It highlights evidence that esketamine produces rapid antidepressant effects and may reduce certain PTSD symptoms, particularly when combined with trauma-focused psychotherapies such as Prolonged Exposure and Eye Movement Desensitization and Reprocessing (EMDR). The article emphasizes the complexity of treating patients with comorbid depression and PTSD, noting challenges related to safety, ethical considerations, and the need for integrated, multimodal treatment approaches. It calls for further rigorous research to expand esketamine’s clinical indications beyond depression while ensuring careful patient selection and monitoring. [Extracted from the article] |
| Copyright of International Journal of Mental Health is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | This article focuses on the clinical use of ketamine and its enantiomer esketamine in treating treatment-resistant depression (TRD) and explores their potential application in posttraumatic stress disorder (PTSD). It highlights evidence that esketamine produces rapid antidepressant effects and may reduce certain PTSD symptoms, particularly when combined with trauma-focused psychotherapies such as Prolonged Exposure and Eye Movement Desensitization and Reprocessing (EMDR). The article emphasizes the complexity of treating patients with comorbid depression and PTSD, noting challenges related to safety, ethical considerations, and the need for integrated, multimodal treatment approaches. It calls for further rigorous research to expand esketamine’s clinical indications beyond depression while ensuring careful patient selection and monitoring. [Extracted from the article] |
|---|---|
| ISSN: | 00207411 |
| DOI: | 10.1080/00207411.2026.2625632 |
